Varumärket DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab, grundat 2010 (United States), från 496 systervarumärken och 17478 konkurrerande varumärken. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab är en del av BRISTOL-MYERS SQUIBB COMPANY, börsnoterat i New York. DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab tillhör affärsområdet Läkemedelstillverkare.

DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab är ett varumärke som tillhör BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheter

BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab) aktiepris

Aktiepris
Popularitet DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab (BRISTOL-MYERS SQUIBB COMPANY)

Popularitet
Hållbarhet BRISTOL-MYERS SQUIBB COMPANY

Hållbarhet
Andra varumärken BRISTOL-MYERS SQUIBB COMPANY

Andra varumärken
Konkurrerande varumärken av DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab

Konkurrerande varumärken
Nyheter

Nyheter

Alla nyheter
BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

Börsen: Mer information om BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab är ett varumärke som tillhör BRISTOL-MYERS SQUIBB COMPANY (BMY) Nyheter

Alla nyheter BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)

Alla nyheter
BRISTOL-MYERS SQUIBB COMPANY (DEMONSTRate: Drug Evalutation in Melanoma: ONcology STudy and Research of Ipilimumab)